Hologen, an AI‑driven biotech co‑founded by former Google CEO Eric Schmidt, is reportedly seeking $150 million to build 'large medicine models' aimed at improving trial signal detection and de‑risking late‑stage studies. The company frames its approach as integrating AI, drug development and investment capabilities to better model treatment heterogeneity. Meanwhile, Insilico Medicine launched Science MMAI Gym, a structured training platform to adapt general large language models for drug discovery tasks like DMPK and toxicity prediction. Both moves highlight growing industry focus on converting general AI into domain‑specific engines for biopharma R&D — a trend drawing capital and strategic partnerships as companies try to commercialize predictive models that can materially shift development timelines.